GlaxoSmithKline is struggling to grow sales post-China bribery scandal, cutting jobs in the U.S. while focusing on a long-term overhaul to manufacturing and R&D to chart some upward momentum. The company was said to be exploring job cuts in China to deliver a much-needed boost to its bottom line, but GSK is refuting those reports, potentially taking a different route to get business back on track.
GlaxoSmithKline has shipped out the first batch of its in-development Ebola vaccine, expecting to kick off late-stage studies in the coming weeks.
In July last year, GlaxoSmithKline submitted its malaria vaccine, RTS,S, for regulatory review by the European Medicines Agency. Because there are no existing malaria vaccines, Glaxo says that a vaccine to be used "alongside other measures such as bed nets and anti-malarial medicines" would be an advance in malaria control. However, a new study published Monday might have GSK rethinking the bed nets.
GlaxoSmithKline is feeling the e-cigarette burn, as sales from the products encroach on its smoking-cessation market share. But the British drugmaker is not planning to join the competition with its own e-cigarette products anytime soon, CEO Andrew Witty told Reuters.
The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.
When GlaxoSmithKline's multibillion-dollar asset swap with Novartis closes this year, don't expect the British pharma giant to stop there, its CEO says--especially when it comes to consumer health.
Months after announcing plans to pursue an IPO for its HIV-focused joint venture, GlaxoSmithKline says it may take a similar tack with some of its other businesses.
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
Bad flu seasons often mean increased sales for drugmakers producing influenza drugs, and companies such as Roche and GlaxoSmithKline stand to benefit the most from this year's growing epidemic.
Roche won FDA approval for a supplemental license application of its chronic lymphocytic leukemia drug Gazyva, strengthening its case over rival GlaxoSmithKline and adding some ammo to its hemo-oncology arsenal.